The benefits of early intervention in obese diabetic patients with FBCx™ — a new dietary fibre
Version of Record online: 2 OCT 2006
Copyright © 2005 John Wiley & Sons, Ltd.
Diabetes/Metabolism Research and Reviews
Volume 23, Issue 1, pages 56–62, January 2007
How to Cite
Grunberger, G., Jen, K.-L. C. and Artiss, J. D. (2007), The benefits of early intervention in obese diabetic patients with FBCx™ — a new dietary fibre. Diabetes Metab. Res. Rev., 23: 56–62. doi: 10.1002/dmrr.687
- Issue online: 28 DEC 2006
- Version of Record online: 2 OCT 2006
- Manuscript Accepted: 13 AUG 2006
- Manuscript Revised: 21 JUL 2006
- Manuscript Received: 26 JAN 2006
- type 2 diabetes;
- weight loss;
- weight management;
- dietary fibre
Obesity and diabetes have become epidemic in the US. Dietary fibres have been reported to reduce the absorption of dietary fat, prevent weight gain, and reduce blood lipid levels. In the current double-blind study, obese patients with type 2 diabetes were recruited for a 3-month study to examine the health effects of a new dietary fibre, FBCx™.
Sixty-six participants were recruited and were randomized into FBCx™ or placebo groups. They were instructed to take two 1-g tablets per fat-containing meal and not to change their eating patterns or daily routine. Three-day dietary records and fasting blood samples were collected prior to enrollment in the study and at the end of months 1, 2 and 3.
Dietary records showed that some participants changed their eating patterns; therefore body weight data were adjusted according to energy intake. As a group, in the 30 days leading into the study, all participants experienced an average weight gain of 1.0 ± 0.4 kg, while those in the placebo group continued to gain weight during the study, those in the FBCx ™ group maintained their weight. Those in the FBCx™ group required more energy to maintain their body weight while those in the placebo group required less (p < 0.05). Participants with hypertriglyceridemia showed a reduction (−0.48 ± 0.24 mmol/L, − 8.2%) in total cholesterol with FBCx™, while those with placebo had an increase (0.24 ± 0.21 mmol/L, 5.2%, p < 0.05). Adiponectin was increased in the FBCx™ but reduced in the placebo group (p < 0.05).
FBCx™ has thus shown promising benefits in weight maintenance, a reduction of blood lipids and an increase in adiponectin levels. It can be easily incorporated into a diabetic management regimen. Copyright © 2006 John Wiley & Sons, Ltd.